Astra Says Potential Blockbuster Reduced High Blood Pressure

AstraZeneca Plc’s experimental hypertension drug Baxdrostat reduced the blood pressure of patients who have an uncontrolled or treatment-resistant form of the condition, boosting the prospects of the medicine becoming a blockbuster.

Patients in a late-stage trial received one of two different doses of Baxdrostat or a placebo drug once a day, the drugmaker said Monday. At 12 weeks those on Baxdrostat had a significant and clinically meaningful reduction in systolic blood pressure, which shows how forcefully the heart is pumping blood into arteries.